Issue 33 - Sep 6, 2019
  • MD Anderson’s Stephen Hahn emerges as candidate for FDA commissioner’s job

    The game of musical chairs involving topmost jobs in oncology has gathered speed and expanded beyond FDA and NCI, pulling in premier positions at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.

  • NCI Director’s Report

    Lowy: NCI needs 15% budget increase to reach FY2021 goal of 15th percentile for paylines

    NCI is requesting an increase of $989 million to its FY2021 budget over FY2019 appropriated levels to boost the institute’s payline, which has dropped to the 8th percentile in FY19—lower than 2013 sequestration levels—and which has been steadily dropping despite increased overall funding in recent years.

  • Guest Editorial

    Skyfall falls to earth

    Why Americans and Russians should be worried

    It’s difficult to discern reason, let alone strategy, in the Russian government’s response after the Skyfall missile (called the 9M730 Burevestnik by the Russian military and SSC-X-9 Skyfall by NATO) exploded during a test Aug. 8.

    The accident occurred in the vicinity of the town of Severodvinsk. A radioactive cloud dispersed by tropospheric winds is easily and rapidly detected outside Russia—so there was no hiding the accident.

  • In Brief

    • Cance named American Cancer Society chief medical and scientific officer 
    • Wakelee named president-elect of IASLC
    • Van Cutsem, Di Leo, Sessa, Swanton win 2019 ESMO awards
    • Tobacco expert Berg joins GWU Cancer Center
    • Bradley named executive vice chairman of Winship Department of Radiation Oncology
    • Lou named CTO medical director and Holtan named CTO-CGI medical director at Masonic Cancer Center 
    • WashU researchers awarded $15 million to study genetic drivers of AML
    • Bowles, Shafer, Pennisi, and Saqib join Inova
    • Blue Cross & Blue Shield of Minnesota and Minnesota Oncology announce five-year collaboration
  • Funding Opportunities

    LLS announces $50 million initiative for pediatric blood cancer research

    The Leukemia & Lymphoma Society announced that it has more than doubled its funding of research focused specifically on childhood blood cancers, adding 20 new research grants valued at more than $13.8 million to its research portfolio in 2019.  

  • TCCL Logo

  • Clinical Roundup

    • Health insurance, ZIP code matters when it comes to benefiting from cancer trials
    • Combination therapy found effective for multiple myeloma patients
    • GSK announces positive results from the DREAMM-2 study for multiple myeloma
  • Drugs & Targets

    • FDA approves entrectinib, third tissue agnostic drug 
    • Syapse, FDA form research collaboration on the regulatory use of real-world evidence
    • Calquence granted Breakthrough Therapy designation for CLL 
    • European Commission approves Empliciti + pomalidomide and dexamethasone for multiple myeloma
    • European Commission approves Imbruvica for expanded use in two indications
    • FDA Grants XTANDI application Priority Review for metastatic hormone-sensitive prostate cancer
    • DARZALEX approved for frontline multiple myeloma in Japan
    • FDA draft guidance encourages inclusion of male patients in breast cancer clinical trials
  • NCI Trials

    NCI Trials for September

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

Issue 34 - Aug 9, 2019
Issue 31 - Aug 2, 2019
  • Conversation with The Cancer Letter

    Sylvester becomes 71st NCI-designated cancer center

    After six years of aggressively recruiting and spending more than $250 million to build up its programs, Sylvester Comprehensive Cancer Center has become the 71st NCI-designated cancer center in the US and the only such institution in South Florida.

  • MD Anderson retains top spot on U.S. News rankings; Johns Hopkins moves up to No. 4

    U.S. News & World Report rankings for 2019-20 significantly reshuffled the top 10 best cancer hospitals, with Johns Hopkins, UPMC, Massachusetts General, and Northwestern moving up the list.

  • In Brief

    • AACR announces new journal, Blood Cancer Discovery
    • Strata Oncology partners with five additional health systems
    • ACS CAN report: Texas must improve cancer-related public policies
    • TCR2 Therapeutics partners with NCI for phase I/II trial of TC-210
  • TCCL Logo

  • Trials & Tribulations

    Barriers to clinical trial enrollment

    Part I of a two-part series

    According to the National Cancer Institute (NCI), 1,735,350 people were newly diagnosed with cancer in 2018. Of those, 65% are expected to achieve remission from their cancer 1. While most physicians agree that clinical trials advance medical knowledge and improve treatment, estimates as low as 2 – 3% of cancer patients enter clinical trials annually 2, 3. Physician knowledge of available clinical trials at their site, training in communication skills and administering clinical trials, and time constraints during patient care time have all been identified as barriers to clinical trial enrollment 1. In addition, strict eligibility criteria and inadequate insurance coverage for required tests may also hinder enrollment.

  • Drugs & Targets

    • FDA approves darolutamide for non-metastatic castration-resistant prostate cancer
    • FDA grants breakthrough designation for NKTR-214 in combination with nivolumab for melanoma
    • EMA adopts positive opinion for Keytruda + Inlyta as first-line for RCC
  • NCI Trials

    NCI Trials for August

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.